Astepro nasal spray is said to be an improvement over the marketed Astelin nasal spray and is better tolerated by patients using the new spray.
Full launch of Astepro in the US will take place well before the next allergic rhinitis season, the company said.
Anders Lonner, CEO of Meda, said: “Our development team has done an excellent work answering the questions from the FDA and reaching approval in such a short time. This is an important milestone for Meda.”